Behandlung der Sialorrhoe mit Botulinum Neurotoxin Typ A – Konsentierte Praxisempfehlungen für Kinder und Erwachsene

  • Wolfgang H Jost
  • Tobias Bäumer
  • Andrea Bevot
  • Ulrich Birkmann
  • Carsten Buhmann
  • Maria Grosheva
  • Orlando Guntinas-Lichius
  • Ute Mlynczak
  • Sebastian Paus
  • Christina Pflug
  • Sebastian Schröder
  • Armin Steffen
  • Bernd Wilken
  • Steffen Berweck

Abstract

Sialorrhea, uncontrolled, excessive drooling, accompanies different, mostly neurological disorders from childhood to adulthood. With incobotulinumtoxinA (Xeomin, IncoBoNT/A, Merz Pharmaceuticals GmbH), an approved medication for the treatment of sialorrhea has been available since 2019. Patient selection, possible therapy goals, treatment and the management of specific treatment situations build the focus of this interdisciplinary expert consensus recommendations with the intent to facilitate access to treatment and to contribute to qualified botulinum toxin therapy.

Bibliographical data

Translated title of the contributionTreatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults
Original languageGerman
ISSN0720-4299
DOIs
Publication statusPublished - 05.2022

Comment Deanary

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PubMed 35453158